Medication & Clinic
Efficacy and safety of butyphthalide sodium chloride injection combined with edaravone in the treatment of acute cerebral infarction
Yinghua Li
Published 2018-03-01
Cite as IMHGN, 2018, 24(5): 723-725. DOI: 10.3760/cma.j.issn.1007-1245.2018.05.032
Abstract
ObjectiveTo explore the efficacy and safety of butyphthalide sodium chloride injection combined with edaravone in the treatment of acute cerebral infarction.
MethodsFrom March 2016 to March 2017, 78 patients with acute cerebral infarction in our hospital were divided into control group and observation group according to the principle of random allocation, 39 cases in each group. The patients in the control group were treated with edaravone, and the patients in the observation group were treated with butyphthalide sodium chloride injection combined with edaravone. The neurological deficit scale (NIHSS) score, serum B type brain natriuretic peptide (BNP) level, total effective rate, and Barthel index (BI) were observed before and after treatment in the two groups.
ResultsAfter the treatment, the NIHSS score and serum BNP level of the observation group were significantly lower than those of the control group (P<0.05); the BI was higher than that of the control group, and the total effective rate was higher than that of the control group (97.44% vs.71.79%) (P<0.05).
ConclusionFor clinical patients with acute cerebral infarction, butyphthalide sodium chloride injection combined with edaravone can obtain better treatment effect, effectively improve the neurological deficit, improve the quality of life, increase the safety.
Key words:
Acute cerebral infarction; Butyphthalide; Edaravone; Safety
Contributor Information
Yinghua Li
Department of Neurology, The People's Hospital of Luyi, Zhoukou 477200, China
